Condition
21-hydroxylase Deficiency
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 1 (2)
Trial Status
Completed3
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT00519818Phase 1Completed
Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia
NCT01862380Not ApplicableUnknown
Adrenocortical Functions in Women With Nonclassical 21-hydroxylase Deficiency.
NCT00542841Not ApplicableCompletedPrimary
Examining Genetic Differences Among People With 21-Hydroxylase Deficiency
NCT01495910Phase 1CompletedPrimary
A Study Examining Doses of Abiraterone Acetate in Adult Women With 21-Hydroxylase Deficiency
Showing all 4 trials